Abstract:In this work, Surface-enhanced Raman spectroscopy (SERS) involving blood plasma was investigated; the objective was to determine whether this approach could distinguish prostate cancer with benign prostatic hyperplasia. The experimental samples were prepared by blood plasma mixed with the silver colloid over an aluminum plate substrate. A total of 14 SERS spectra for prostate cancer (PCa) and 14 spectra for benign prostatic hyperplasia (BPH) were successfully gathered from patients who came from Fujian Provincial Hospital. Difference spectrum analysis combined with the assignment of Raman bands indicated that there were subtle but distinct changes between prostate cancer (PCa) and benign prostatic hyperplasia (BPH), which could be related to the level of prostate specific antigen (PSA); because it has been reported that the level of PSA is increased in men who have prostate cancer compared with those with benign prostatic hyperplasia (BPH). To further make clear the difference of Prostate cancer (PCa) and benign prostatic hyperplasia (BPH), the spectral data was combined with multivariate analysis processes. Principal component analysis (PCA), as a spectral dimensionality reduction approach, and in conjunction with linear discriminant analysis (LDA) were employed to identify the samples, to build diagnostic algorithms. The leave-one-out cross-validation method was used to validate the diagnostic algorithms; the result showed that a sensitivity of 95.8% and a specificity of 100.0% which indicated can significantly differentiate PCa and BPH groups. In addition, we further verify the validity of the diagnosis algorithm based on PCA-LDA diagnosis algorithm by using receiver operating characteristic (ROC) curves. The results of experiment study suggest that SERS combined with PCA-LDA algorithms has great potential for clinical screening of benign prostate hyperplasia and prostate cancer.

SERS-based biosensor for detection of f-PSA%: Implications for the diagnosis of prostate cancer

Comparison of oligonucleotide-labeled antibody probe assays for prostate-specific antigen detection.

Portable SERS-based lateral flow immunoassay strips with self-calibration for detection of a prostate cancer biomarker

Ultrasensitive Detection of Prostate-Specific Antigen Using a SERS-Based Magnetic Immunosensor

Simultaneous Immunoassays of Dual Prostate Cancer Markers Using a SERS-based Microdroplet Channel.

Synergistic enhancement mediated sensitive SERS-based immunoassay of PSA using versatile PDMS@AgNPs@ZIF-67 biomimetic substrates

SERS-Based Pump-Free Microfluidic Chip for Highly Sensitive Immunoassay of Prostate-Specific Antigen Biomarkers

DNA tetrahedron-mediated immune-sandwich assay for rapid and sensitive detection of PSA through a microfluidic electrochemical detection system

A highly sensitive ratiometric electrochemical aptasensor for prostate specific antigen detection based on toehold-mediated strand displacement reaction

Quantitative and Recyclable Surface-Enhanced Raman Spectroscopy Immunoassay Based on Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>@Ag Core-Shell Nanoparticles and Au Nanowire/Polydimethylsiloxane Substrates

Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry

An electrochemical/SERS dual-mode immunosensor using TMB/Au nanotag and Au@2D-MoS2 modified screen-printed electrode for sensitive detection of prostate cancer biomarker

Simultaneous detection of dual biomarkers using hierarchical MoS2 nanostructuring and nano-signal amplification-based electrochemical aptasensor toward accurate diagnosis of prostate cancer

A Label-free Electrochemical Immunosensor Based on Gold Nanoparticles-poly(ferriporphyrin-co-acrylamide)-reduced Graphene Oxide and the Application in Prostate Specific Antigen Detection

A label-free fluorescent aptasensor based on HCR and G-quadruplex DNAzymes for the detection of prostate-specific antigen

Ratio fluorescence/colorimetric dual mode aptasensor and smartphones-assisted miniaturized device for early diagnosis of prostate cancer

Label-free detection of prostate cancer and benign prostatic hyperplasia based on SERS spectroscopy of Plasma

Fluorescent Immunosensor Based on CuS Nanoparticles for Sensitive Detection of Cancer Biomarker

Target-aptamer binding triggered isothermal strand displacement polymerase reaction for prostate specific antigen detection

A sensitive label-free biosensor based on Ag 2 S-sensitived Bi 2 WO 6 /BiOBr heterojunction for photoelectrochemical immunoassay of prostate specific antigen

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL.